CINECA IRIS Institutional Research Information System

BUTTIGLIERO, Consuelo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.888
EU - Europa 2.601
AS - Asia 1.929
OC - Oceania 124
SA - Sud America 106
AF - Africa 70
Continente sconosciuto - Info sul continente non disponibili 10
Totale 8.728
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.726
CN - Cina 889
IT - Italia 705
IE - Irlanda 293
GB - Regno Unito 225
SG - Singapore 224
JP - Giappone 217
SE - Svezia 208
FR - Francia 169
DE - Germania 168
CA - Canada 132
UA - Ucraina 121
AT - Austria 116
AU - Australia 116
IN - India 115
ES - Italia 109
PL - Polonia 83
VN - Vietnam 79
HK - Hong Kong 76
KR - Corea 72
FI - Finlandia 62
NL - Olanda 59
TW - Taiwan 54
TR - Turchia 53
BE - Belgio 42
BR - Brasile 41
GR - Grecia 35
DK - Danimarca 29
IR - Iran 28
CH - Svizzera 27
PT - Portogallo 27
RU - Federazione Russa 26
CO - Colombia 23
MX - Messico 22
PH - Filippine 19
CL - Cile 18
IL - Israele 18
RO - Romania 16
TH - Thailandia 16
ID - Indonesia 13
NO - Norvegia 13
KE - Kenya 12
ZA - Sudafrica 12
RS - Serbia 11
EG - Egitto 10
EU - Europa 10
MY - Malesia 10
CZ - Repubblica Ceca 9
HR - Croazia 9
MA - Marocco 9
PK - Pakistan 9
EC - Ecuador 8
HU - Ungheria 8
IQ - Iraq 8
LB - Libano 8
NG - Nigeria 8
NZ - Nuova Zelanda 8
SK - Slovacchia (Repubblica Slovacca) 8
LT - Lituania 7
GH - Ghana 6
MO - Macao, regione amministrativa speciale della Cina 6
PE - Perù 6
SI - Slovenia 6
AR - Argentina 4
BG - Bulgaria 4
LY - Libia 3
NI - Nicaragua 3
SN - Senegal 3
SY - Repubblica araba siriana 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
BJ - Benin 2
CU - Cuba 2
KW - Kuwait 2
KZ - Kazakistan 2
LV - Lettonia 2
MT - Malta 2
NE - Niger 2
PR - Porto Rico 2
AM - Armenia 1
BO - Bolivia 1
CG - Congo 1
CY - Cipro 1
EE - Estonia 1
GE - Georgia 1
JM - Giamaica 1
JO - Giordania 1
LU - Lussemburgo 1
MN - Mongolia 1
PY - Paraguay 1
SA - Arabia Saudita 1
TN - Tunisia 1
UY - Uruguay 1
ZM - Zambia 1
Totale 8.728
Salva come PNG Salva come JPEG
Città #
Chandler 448
Dublin 283
Beijing 259
Fairfield 200
Redwood City 171
Houston 170
Ashburn 160
Singapore 152
Wilmington 133
Nyköping 132
Torino 127
Woodbridge 111
Seattle 109
Vienna 102
Shanghai 89
Pisa 86
Turin 81
Tokyo 75
Ann Arbor 74
Guangzhou 74
Cambridge 67
Jacksonville 61
Villeurbanne 61
Princeton 60
Medford 59
Dong Ket 51
Warsaw 49
Dearborn 44
Nanjing 43
London 42
New York 39
Boston 36
Chengdu 36
Fremont 36
Taipei 34
Milan 29
Santa Clara 29
Toronto 26
Hangzhou 25
Duncan 24
San Diego 23
Changsha 22
Wuhan 22
Binbrook 20
Jinan 20
Los Angeles 20
Athens 19
Paris 19
Chicago 18
Hong Kong 18
Kalundborg 18
Brisbane 17
Helsinki 17
Madrid 17
Sydney 17
Peoria 16
Boardman 15
Seoul 15
Central District 14
Istanbul 14
Philadelphia 14
Québec 14
Raritan 14
Rome 14
Shenyang 14
Bengaluru 13
Montréal 13
Santiago 13
Zhengzhou 13
Berlin 11
Lappeenranta 11
Chennai 10
Chongqing 10
Evanston 10
Genoa 10
Kolkata 10
Minneapolis 10
Norwalk 10
San Francisco 10
Sewell 10
São Paulo 10
Tianjin 10
Belgrade 9
Brussels 9
Fuzhou 9
Hamburg 9
Hefei 9
Kunming 9
Ottawa 9
Vancouver 9
Ankara 8
Buffalo 8
Derby 8
Frankfurt am Main 8
Montreal 8
Nijmegen 8
Piemonte 8
Adelaide 7
Atlanta 7
Barcelona 7
Totale 4.651
Salva come PNG Salva come JPEG
Nome #
Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: A systematic review and meta-analysis 1.166
Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer 1.162
Hormonal treatment and quality of life of prostate cancer patients: new evidences 702
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer 500
Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer 484
Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer 345
The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome 271
Renal cell carcinoma (RCC): Fatter is better? A review on the role of obesity in RCC 226
Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era 214
Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer 162
Pros-IT CNR: an Italian prostate cancer monitoring project 147
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment 145
Immediate or delayed nephrectomy in patients with metastatic renal cancer who are receiving targeted agents: Is the analysis at risk for guarantee- time bias? 134
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: The Pros-IT CNR study 129
C28Sequencing cabazitaxel and new generation hormonal treatments in metastatic castration resistant prostate cancer patients after first line docetaxel: a retrospective analysis 129
Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: Results of an Italian multicentre study 113
Enzalutamide-resistant castration-resistant prostate cancer: Challenges and solutions 109
Immunotherapy for patients with advanced urothelial cancer: Current evidence and future perspectives 102
An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer 101
Androgen deprivation modulates gene expression profile along prostate cancer progression 94
223Ra Dichloride Bone-Targeted Therapy in a Case of Metastatic Salivary Duct Carcinoma 92
Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate 91
Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma 86
Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer. 85
Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel 85
LATITUDE and other coordinates in quality of life of prostate cancer patients 82
Effects of Serum Testosterone Levels After 6 Months of Androgen Deprivation Therapy on the Outcome of Patients With Prostate Cancer. 82
PROGNOSTIC ROLE OF SERUM TESTOSTERONE LEVELS IN PROSTATE CANCER PATIENTS DURING ANDROGEN-DEPRIVATION THERAPY 80
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma. 71
Zoledronic Acid Dosing Interval for Metastatic Cancer 69
Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic review. 63
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents 62
Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside 59
68 Ga-PSMA Uptake in Fibrous Dysplasia 58
How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study 58
Pitfalls in the diagnosis of adrenocortical tumors: A lesson from 300 consultation cases 57
Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018 57
Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel 54
Endocrine therapy plus zoledronic acid in premenopausal breast cancer 50
Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences 49
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer 49
Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives 48
Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review 47
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 45
On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2 45
Prognostic factors in metastatic castration resistant prostate cancer patients treated with Radium-223: a retrospective study 45
Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs 43
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer 41
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with Abiraterone or Enzalutamide 41
Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report 41
Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis 41
Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine? 37
New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine? 36
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy 34
De novo metastatic castration sensitive prostate cancer: State of art and future perspectives 33
Prognostic role of early PSa drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide 33
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial 33
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16) 32
Darolutamide in Metastatic Prostate Cancer 32
Pathological and molecular features of adrenocortical carcinoma: an update 31
Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications 31
Therapeutic sequencing in advanced renal cell carcinoma: how to choose considering clinical and biological factors 30
Evaluation of cognitive function in trials testing new-generation hormonal therapy in patients with prostate cancer: A systematic review 30
The prognostic value of pain in castration-sensitive prostate cancer 26
New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond 25
Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough? 25
Prognostic Role of Serum Parathyroid Hormone Levels in Advanced Prostate Cancer Patients Undergoing Zoledronic Acid Administration 25
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin 23
How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy? 21
How Does Environmental and Occupational Exposure Contribute to Carcinogenesis in Genitourinary and Lung Cancers? 18
Non-invasive detection of neuroendocrine prostate cancer through targeted cell-free DNA methylation 17
Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review 16
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study 15
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort 15
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) 13
Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis 13
Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma 12
Antiandrogens as Therapies for COVID-19: A Systematic Review 12
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses 11
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network 11
Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer 11
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study 9
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis 6
Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials 5
Safety profile of darolutamide versus placebo: a systematic review and meta-analysis 4
Totale 9.036
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.951
article - articoli 0
book - libri 0
conference - conferenze 278
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.229
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.113 0 0 51 136 73 140 132 111 177 112 90 91
2020/20211.096 57 99 84 101 117 92 98 57 79 84 74 154
2021/20221.118 78 79 67 86 63 41 62 53 69 93 288 139
2022/20231.929 129 192 73 148 184 401 122 152 213 89 132 94
2023/20241.164 116 159 71 111 81 141 86 75 21 81 101 121
2024/2025299 76 191 32 0 0 0 0 0 0 0 0 0
Totale 9.036